Wedbush Securities Inc. Has $2.10 Million Stake in Gilead Sciences, Inc. (GILD)
Wedbush Securities Inc. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 36.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,272 shares of the biopharmaceutical company’s stock after selling 18,615 shares during the period. Wedbush Securities Inc.’s holdings in Gilead Sciences were worth $2,098,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Athena Capital Advisors LLC acquired a new position in Gilead Sciences during the fourth quarter worth about $27,000. Capital Financial Planning LLC acquired a new position in Gilead Sciences during the fourth quarter worth about $27,000. Advisors Preferred LLC acquired a new position in Gilead Sciences during the fourth quarter worth about $31,000. Legacy Financial Advisors Inc. raised its position in Gilead Sciences by 361.3% during the fourth quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 383 shares during the last quarter. Finally, Claybrook Capital LLC acquired a new position in Gilead Sciences during the fourth quarter worth about $32,000. 80.20% of the stock is currently owned by institutional investors and hedge funds.
In related news, Director Gayle E. Wilson sold 19,068 shares of the company’s stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the completion of the transaction, the director now owns 143,567 shares of the company’s stock, valued at $9,630,474.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John Francis Cogan sold 2,700 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $65.07, for a total transaction of $175,689.00. Following the transaction, the director now directly owns 57,560 shares of the company’s stock, valued at approximately $3,745,429.20. The disclosure for this sale can be found here. In the last three months, insiders sold 42,102 shares of company stock valued at $2,787,375. Company insiders own 0.20% of the company’s stock.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing analysts’ consensus estimates of $1.70 by ($0.26). The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.52 billion. Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The business’s quarterly revenue was down 2.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.78 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 6.23 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.00%. The ex-dividend date was Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s payout ratio is currently 40.98%.
A number of equities analysts have issued reports on GILD shares. ValuEngine cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, February 13th. Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Friday, March 22nd. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, February 7th. Wells Fargo & Co cut their target price on shares of Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating for the company in a research report on Tuesday, February 5th. Finally, Oppenheimer upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 target price for the company in a research report on Thursday, January 3rd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $82.12.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
See Also: Gap Up Stocks
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.